The Regulator

$249 million: that is the Rural Health Transformation Program money the Centers for Medicare & Medicaid Services (CMS) announced October 22 for Alaska, spread across 254 projects. The award completes Alaska’s first-year funding cycle in the $50 billion program. CMS says the money will pay for a telehealth network linking village clinics, health aides, doulas and lactation specialists to pregnancy and postpartum care in 32 Interior communities, portable X-ray units in Northwest Arctic village clinics, and cellular remote monitoring for patients in Nome and 15 nearby villages. A Galena program will also let high school students earn nursing assistant credentials before graduation. Who it hits: Alaska clinics, tribal and village health programs, and the vendors who supply telehealth and diagnostic equipment. So what: the release names no recipients, no per-project amounts and no deadlines, so providers cannot yet tell who is funded. Senator Dan Sullivan cited $1.4 billion over five years for the state, a figure from his statement, not CMS’s. Confidence: High on the announcement and totals; Low on who receives what. Sources: CMS press release.

Texas: CMS announced another $8 million for 28 rural providers under a “Rural Texas Strong” initiative. The October 22 release says the money targets chronic disease prevention and management, including diabetes, cardiovascular and chronic respiratory disease, recruiting physicians and emergency medical personnel, and replacing aging equipment and facilities. It names only a few recipients, among them Sudan Medical Clinic in Lamb County and Best Value Medical Center Pharmacy in Glen Rose, and gives no per-award amounts. CMS calls the $8 million one part of a larger fiscal 2026 award to Texas and does not say how it relates to the earlier Texas announcement we covered October 16. Confidence: High on the announcement; Low on how it fits the state total. Sources: CMS press release.

An executive order gives HHS 90 days to create a Women’s Health Division at the National Institutes of Health. Executive Order 14437, signed October 19 and published in the Federal Register October 22, directs the Department of Health and Human Services (HHS), through the NIH director, to set up the division and work with the NIH Office of Research on Women’s Health on understudied conditions, replication studies, data collection and enforcement of the sex-as-a-biological-variable policy for grant recipients. It also creates a White House Women’s Health Task Force co-chaired by the HHS Secretary and the White House chief of staff, with members including the FDA Commissioner, the CDC Director, the NIH Director and the CMS Administrator. It revokes Executive Order 14120 of March 2024 and a November 2023 presidential memorandum. So what: no dollars are attached, and the order is subject to the availability of appropriations, so research grants will depend on Congress. Confidence: High. Sources: White House executive order text, Federal Register, Executive Order 14437 (2026-21666).

The Food and Drug Administration (FDA) launched a program to coordinate brain and nervous-system product development, starting with Alzheimer’s prevention. The Neuroscience Advancement and Innovation Nexus, announced October 22, brings the agency’s drug, biologics and device centers together on scientific and regulatory questions for neurologic and psychiatric disorders, substance use disorders and pain. Its first initiative, the Alzheimer’s Prevention Accelerator, will explore trial populations, endpoints and ways to show that cognitive decline is delayed or prevented. Who it hits: drug and device developers running neurology trials. So what: the FDA announced no dollars and no deadlines, so it is a signal of regulatory direction, not a rule. Confidence: High on the announcement; Low on any effect on approval timelines. Sources: FDA press announcement.

The FDA published draft guidance October 23 setting cadmium action levels for processed foods for babies and children under 2. Once final, the guidance would set levels the agency considers achievable and intended to further reduce cadmium in the food supply. Comments are due December 22, 2026. Who it hits: makers of infant and toddler foods. So what: FDA guidance does not itself bind industry, but action levels signal where the agency may act against products. I could not retrieve the full text, so the numeric levels are not confirmed here. Confidence: High on the draft and deadline; Low on the numbers. Sources: Federal Register, cadmium draft guidance notice (2026-21670).

The FDA finalized its question-and-answer guidance on mandatory cosmetics recalls. Per the Federal Register notice published October 23, the guidance covers the criteria, process and expectations for recalls the agency orders, and finalizes a draft published December 18, 2025. Who it hits: cosmetics manufacturers, packers and distributors. So what: companies can now plan recall procedures against a final document; the notice lists no effective date or comment deadline, and I could not retrieve the full text. Confidence: High on the finalization; Low on specifics. Sources: Federal Register, cosmetics recall guidance notice (2026-21679).